1. Articles in category: General

    1-24 of 278 1 2 3 4 ... 10 11 12 »
    1. Zebrafish as a model to study neuroblastoma development.

      Zebrafish as a model to study neuroblastoma development.

      Cell Tissue Res. 2017 Oct 13;:

      Authors: Casey MJ, Stewart RA

      Abstract Neuroblastoma is a pediatric solid tumor arising from embryonic neural crest progenitor cells that normally generate the peripheral sympathetic nervous system.

      Read Full Article
      Mentions: ALK
    2. Nutritional Characteristics of the Diets of Child and Adolescent Cancer Survivors.

      Nutritional Characteristics of the Diets of Child and Adolescent Cancer Survivors.

      J Adolesc Young Adult Oncol. 2017 Oct 12;:

      Authors: Teixeira JFC, Maia-Lemos PDS, Pisani LP

      Abstract PURPOSE: Diseases associated with prior treatment, such as obesity, have been described in cancer survivors. Recent studies have shown that current estimates of overweight do not differ from that in the general population, suggesting the influence of environmental factors, such as dietary intake.

      Read Full Article
      Mentions: Treatment
    3. p53 non-genotoxic activation and mTORC1 inhibition lead to effective combination for neuroblastoma therapy.

      p53 non-genotoxic activation and mTORC1 inhibition lead to effective combination for neuroblastoma therapy.

      Clin Cancer Res. 2017 Aug 18;:

      Authors: Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan S, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E

      Read Full Article
    4. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.

      "NB-mRNA was detectable in 83% of BM (185/223) and 63% (89/142) of blood specimens, and their DCts were correlated (Spearman r=0.67, p<0.0001) although BM Ct was 7.9±0.5 Ct stronger than blood Ct. When BM morphology, MIBG, or CT/MRI were positive, NB-mRNA was detected in 99% (99/100), 88% (100/113), and 81% (82/101) of BMs. When all three were negative, NB-mRNA was detected in 55% (11/20) of BMs. BM NB-mRNA correlated with BM morphology or MIBG positivity (p<0.0001 and p=0.007). BM and blood ΔCts ...

      Read Full Article
    5. Chemoimmunotherapeutic effect of combined treatment with ex vivo generated antigen-presenting immune cells and conventional antitumor agents in a mouse neuroblastoma model.

      Chemoimmunotherapeutic effect of combined treatment with ex vivo generated antigen-presenting immune cells and conventional antitumor agents in a mouse neuroblastoma model.

      J Pediatr Surg. 2017 Apr 21;:

      Authors: Inoue S, Setoyama Y, Odaka A, Kitagawa D, Beck Y

      Read Full Article
      Mentions: Treatment
    6. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

      The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

      Cancer Lett. 2017 Apr 25;:

      Authors: Lu J, Guan S, Zhao Y, Yu Y, Woodfield SE, Zhang H, Yang KL, Bieerkehazhi S, Qi L, Li X, Gu J, Xu X, Jin J, Muscal JA, Yang T, Xu GT, Yang J

      Read Full Article
      Mentions: ALK MYCN
    7. Impact of shared care program in follow-up of childhood cancer survivors: An intervention study

      With the growing rate of childhood cancer cure and the risks of sequelae, long-term follow-up (FU) of survivors is a central issue. Several models have been proven far from satisfactory. Shared care FU is the result of collaboration between general practitioners (GPs) and cancer centers. We sought to demonstrate the feasibility of setting up a shared care program based on the patient-centered education of GPs and to evaluate the impact of this model in an intervention study.

      Read Full Article
    8. Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.

      Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.

      Pediatr Hematol Oncol. 2016 May;33(4):264-75

      Authors: Theruvath J, Russo A, Kron B, Paret C, Wingerter A, El Malki K, Neu MA, Alt F, Staatz G, Stein R, Seidmann L, Prawitt D, Faber J

      Read Full Article
      Mentions: ALK
    9. Prominent Pulmonary Metastases Without Concurrent Osseous Involvement in Patients With High-Risk Neuroblastoma.

      Prominent Pulmonary Metastases Without Concurrent Osseous Involvement in Patients With High-Risk Neuroblastoma.

      Clin Nucl Med. 2017 Feb 13;:

      Authors: Bai X, Zhuang H

      Abstract Metastases from high-risk neuroblastomas generally are to the bone or bone marrow. Multiple lung metastases are rare, especially when there was no concurrent osseous metastasis. We report 2 cases of high-risk neuroblastomas having prominent lung metastases without concurrent osseous lesion observed.

      Read Full Article
    10. Parent illness appraisals, parent adjustment, and parent-reported child quality of life in pediatric cancer.

      "The goal of the present study was to examine the interrelationships among multiple parent illness appraisals, parent adjustment outcomes, and parent-reported child quality of life in parents of children diagnosed with cancer. Parents completed measures of illness appraisal (illness uncertainty and attitude toward illness), parent adjustment (general distress, posttraumatic stress, parenting stress), and child quality of life (general and cancer-related). Path analysis revealed direct effects for parent illness uncertainty and illness attitudes on all 3 measures of parent adjustment. Illness uncertainty, but not illness attitudes, demonstrated a direct effect on parent-reported child general quality of life; parenting stress had direct ...

      Read Full Article
    11. Medical management of side effects related to CAR T cell therapy in hematologic malignancies.

      Medical management of side effects related to CAR T cell therapy in hematologic malignancies.

      Expert Rev Hematol. 2016 May 3;

      Authors: Namuduri M, Brentjens RJ

      Abstract CD19-targeted Chimeric Antigen Receptor (CAR) T cells have shown impressive success and drastically improved clinical outcomes in relapsed/refractory B-cell malignancies, especially acute lymphoblastic leukemia. However, some unique, mostly reversible toxicities are observed with this novel immunotherapeutic approach.

      Read Full Article
      Mentions: Side Effects
    12. Feasibility of Early Palliative Care Consultation for Children With High-Risk Malignancies

      Children with cancer suffer significant morbidity throughout therapy and often face an uncertain prognosis. Because palliative care teams can provide an additional layer of support with symptom management and communication, we conducted a prospective study assessing the feasibility of early palliative care consultation for children with high-risk malignancies.

      Read Full Article
    13. News digest – Cancer’s ‘Achilles heel’, e-cigs, vegan diets and… condoms cause cancer?

      News digest – Cancer’s ‘Achilles heel’, e-cigs, vegan diets and… condoms cause cancer?
      • Our scientists uncovered a potential ‘Achilles heel’ on the surface of cancer cells, which helps give us important clues that could one day lead to personalised treatments using patients’ own immune systems. The BBC, Guardian, Financial Times and many more covered this story. And here’s our press release and blog post for the full scoop on the story.
      Read Full Article
    14. Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors

      Natural killer (NK) cells with mismatched killer cell immunoglobulin-like receptor–ligand pairs have shown efficacy and been proven safe in treatment of cancer patients. Ex vivo–expanded and highly activated NK cells (MG4101) had been generated under good manufacturing practice conditions, which demonstrated potent anticancer activity in vitro and in vivo in preclinical studies.

      Read Full Article
      Mentions: NK Cells
    15. PD-1 Blockade Expands Intratumoral Memory T Cells

      Tumor responses to programmed cell death protein 1 (PD-1) blockade therapy are mediated by T cells, which we characterized in 102 tumor biopsies obtained from 53 patients treated with pembrolizumab, an antibody to PD-1. Biopsies were dissociated, and single-cell infiltrates were analyzed by multicolor flow cytometry using two computational approaches to resolve the leukocyte phenotypes at the single-cell level.

      Read Full Article
      Mentions: Antibody PD-1
    16. Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium, a Major Milestone in the War on Cancer in Children

      PHOENIX--(BUSINESS WIRE)--In a press conference today, Cancer MoonShot 2020 announced another milestone in its quest to alter the course of cancer care with the formation of the Pediatrics Consortium focused on bringing the promise of combined immunotherapy as the next-generation standard of cancer care to children diagnosed with the disease. With leadership at Phoenix Children’s Hospital helping to initiate this consortium, all founding partners will seek to apply the most comprehensive cancer

      Read Full Article
      Mentions: Immunotherapy
    17. Immunotherapy cancer ‘cure’ headlines distract from fascinating science

      Immunotherapy cancer ‘cure’ headlines distract from fascinating science

      The undoubted promise of cancer immunotherapy is never far from the headlines. And waking up this morning, we heard claims that a new immune therapy may offer hope of ‘lasting cures’ for cancer.

      The news comes from a conference in Washington DC in the US. And while the science is extremely exciting, the media’s response has jumped the gun a little.

      Read Full Article
      Mentions: Immunotherapy
    18. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.

      "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.

      Expert Opin Biol Ther. 2016 Feb 5;

      Authors: Thakur A, Lum LG

      Abstract FUNDING SOURCE: Funding was supported by National Cancer Institute of the NIH under award numbers CA092344, CA140314, and Young Family Foundation and the Raymond Neag Foundation. CONFLICT OF INTEREST: L.G.L. is co-founder of Transtarget Inc. and A.T. is co-founder of Nova Immune Platform.

      Read Full Article
    1-24 of 278 1 2 3 4 ... 10 11 12 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles